FEATURED NEWS

• HDA Statement on the Ensuring Patient Access and Effective Drug Enforcement Act

  September 13, 2019

  The Healthcare Distribution Alliance (HDA) released the following statement regarding media reporting on the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.

• HDA Statement on HHS-FDA "Safe Importation Action Plan"

  July 31, 2019

  The Healthcare Distribution Alliance (HDA) released the following statement on the release of the “Safe Importation Action Plan” by the Department of Health and Human Services (HHS) and U.S. Food and Drug Administration (FDA).

• New Analysis Notes the Critical and Evolving Role Pharmaceutical Distributors Play in U.S. Healthcare

  July 30, 2019

  A new report published by the Healthcare Distribution Alliance (HDA) and Deloitte Consulting LLP highlights the value distributors provide to the United States healthcare ecosystem and estimates pharmaceutical distributors generate between $33 and $53 billion in cost savings annually. The Role of Distributors in the US Health Care Industry provides insights into the importance of wholesalers in driving efficiency and innovation across the pharmaceutical supply chain — both today and over the next several years.

• HDA Statement on Release of DEA ARCOS Data

  July 16, 2019

  Healthcare Distribution Alliance (HDA) Senior Vice President of Communications John Parker released the following statement on the release of the Drug Enforcement Administration’s (DEA) Automation of Reports and Consolidated Orders System (ARCOS) data.

• Analysis: Importation Policies Cost-Prohibitive to U.S. Healthcare System, Pose Risks to Patients

  July 15, 2019

  A new report published by the HDA Research Foundation concludes that federal proposals to permit the importation of prescription drugs into the U.S. fail to provide comprehensive guidance and funding to meet current federal safety and quality standards. As highlighted in the report, “The Risks and Realities of Commercial Drug Importation,” implementation of these policies would result in at least $1.1 billion in costs due to patient risks, required federal regulatory oversight and the operational challenges placed on the supply chain.